Skip to main content
Contact Us
Subscribe
E-Edition
76°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Biogen Inc.
< Previous
1
2
Next >
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
October 30, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
October 29, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
October 29, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
October 28, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
October 26, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
October 24, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
October 22, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
October 09, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
October 08, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
IONS
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
September 24, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen Board Appoints Two New Independent Directors
September 12, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
September 04, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
IONS
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC)
July 30, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
July 30, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
DHR
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
July 26, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen Completes Acquisition of Human Immunology Biosciences
July 02, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
June 27, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
June 09, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel
June 03, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
May 30, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
May 22, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
IONS
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
May 14, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen Reports Progress on Corporate Responsibility Priorities
May 02, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
March 06, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
IONS
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
March 04, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
February 23, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
February 12, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen to Realign Resources for Alzheimer's Disease Franchise
January 31, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
December 19, 2023
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.